Trích dẫn APA

Nakamoto, S., Ikeda, M., Kubo, S., Yamamoto, M., Yamashita, T., & Notsu, A. (2021). Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer. Sci Rep.

Trích dẫn kiểu Chicago

Nakamoto, Shogo, Masahiko Ikeda, Shinichiro Kubo, Mari Yamamoto, Tetsumasa Yamashita, và Akifumi Notsu. "Systemic Immunity Markers Associated With Lymphocytes Predict the Survival Benefit From Paclitaxel Plus Bevacizumab in HER2 Negative Advanced Breast Cancer." Sci Rep 2021.

Trích dẫn MLA

Nakamoto, Shogo, et al. "Systemic Immunity Markers Associated With Lymphocytes Predict the Survival Benefit From Paclitaxel Plus Bevacizumab in HER2 Negative Advanced Breast Cancer." Sci Rep 2021.

Cảnh báo: Các trích dẫn này có thể không phải lúc nào cũng chính xác 100%.